AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30087216 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (6 g/d for 8 weeks)
Number of subjects: 34
Study 30087216 — intervention group
Group type: COMPARATOR
Intervention: Medium chain triglycerides oil (6 g/d for 8 weeks)
Number of subjects: 34
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid intake along with antimyeloma therapy
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cutoff hemodialysis membranes in combination with antimyeloma therapy
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-based regimens
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m(2) to 140 mg/m(2))
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Number of subjects: 0
Study 26976420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib in combination with lenalidomide and dexamethasone
Number of subjects: 0
Study 25010566 — intervention group
Group type: EXPERIMENTAL
Intervention: Handling in lateral decubitus
Number of subjects: 31
Study 25010566 — intervention group
Group type: EXPERIMENTAL
Intervention: Handling in ventral decubitus
Number of subjects: 31
Study 22921891 — intervention group
Group type: EXPERIMENTAL
Intervention: E3 allele presence
Number of subjects: 843
Study 22921891 — intervention group
Group type: EXPERIMENTAL
Intervention: E4 allele presence
Number of subjects: 843
Study 22921891 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 allele presence
Number of subjects: 843
Study 20605504 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for chest symptoms related to TB and collection of sputum samples; methods: Ziehl‐Neelsen smear microscopy and solid media culture.
Number of subjects: 11468
Study 17585311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 30
Study 17585311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 30
Study 17585311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15704776 — intervention group
Group type: EXPERIMENTAL
Intervention: IJ-CVLP training
Number of subjects: 47
Study 14533654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ingestion of biogenic amines (specific types not detailed)
Number of subjects: 10
Study 14533654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine
Number of subjects: 10
Study 14533654 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylethylamine in chocolate
Number of subjects: 10
Study 10608589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg)
Number of subjects: 14
Study 10608589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7851578 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA; Lupron) 0.1 mg SC daily for 3 months
Number of subjects: 40
Study 7851578 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (Danocrine) 800 mg orally daily for 3 months
Number of subjects: 40
Study 1659236 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone maintenance clinic
Number of subjects: 301
Study 1659236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 301
Study 6108895 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg tiotidine
Number of subjects: 0
Study 6108895 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg tiotidine
Number of subjects: 0
Study 6108895 — intervention group
Group type: COMPARATOR
Intervention: 300 mg cimetidine
Number of subjects: 0
Study 31950152 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol tolerance assessment
Number of subjects: 0
Study 31950152 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel medications co-administered with alcohol
Number of subjects: 0
Study 30706865 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual microscopy (VM)
Number of subjects: 64
Study 30706865 — intervention group
Group type: COMPARATOR
Intervention: Light microscopy (LM)
Number of subjects: 64
Study 28646807 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaltenborn‐Evjenth orthopedic manual therapy (KEOMT) combined with cryotherapy (KEOMT‐C)
Number of subjects: 40
Study 28646807 — intervention group
Group type: COMPARATOR
Intervention: Kaltenborn‐Evjenth orthopedic manual therapy (KEOMT) combined with Kinesio taping (KEOMT‐K)
Number of subjects: 40
Study 25644582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 14
Study 25644582 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 14
Study 25644582 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 14
Study 25644582 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 14
Study 24317968 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance + impact training
Number of subjects: 67
Study 24317968 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study 22402257 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 mcg/drsp 3 mg in a 21/7-day regimen
Number of subjects: 53
Study 19671292 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal group (Group M) with intravenous fentanyl and atracurium, inhalation of nitrous oxide/oxygen (50%:50%) and sevoflurane (5%)
Number of subjects: 54
Study 19671292 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal group (Group M)
Number of subjects: 54
Study 19671292 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) with inhalation of nitrous oxide/oxygen (50%:50%) and sevoflurane (5%)
Number of subjects: 54
Study 19671292 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 54
Study 17296408 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanner
Number of subjects: 186
Study 17722318 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg oral misoprostol
Number of subjects: 146
Study 17722318 — intervention group
Group type: COMPARATOR
Intervention: 25 microg vaginal misoprostol
Number of subjects: 146
Study 17722318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 12374912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass grafting
Number of subjects: 14
Study 12374912 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted sites
Number of subjects: 14
Study 10195521 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnographic determination of ETCO2
Number of subjects: 38
Study 10195521 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 38
Study 10195521 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal detection method (EDM) using a self‐inflating bulb
Number of subjects: 38
Study 10195521 — intervention group
Group type: EXPERIMENTAL
Intervention: Transillumination method using a lighted stylet (Trachlight)
Number of subjects: 38
Study 10195521 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all four methods
Number of subjects: 38
Study 7591353 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap opera videotape
Number of subjects: 0
Study 7591353 — intervention group
Group type: EXPERIMENTAL
Intervention: Rap videotape
Number of subjects: 0
Study 7591353 — intervention group
Group type: COMPARATOR
Intervention: Combined videotapes (soap opera and rap)
Number of subjects: 0
Study 7591353 — intervention group
Group type: COMPARATOR
Intervention: Discussion group control
Number of subjects: 0
Study 2274744 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate (2.0 g/day)
Number of subjects: 0
Study 2274744 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1.2 g/day)
Number of subjects: 0
Study 7030652 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide aerosol 0.5 mg (two inhalations) twice daily
Number of subjects: 32
Study 7030652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28763311 — intervention group
Group type: EXPERIMENTAL
Intervention: PEWS Model 1
Number of subjects: 108
Study 28763311 — intervention group
Group type: EXPERIMENTAL
Intervention: PEWS Model 2
Number of subjects: 108
Study 28763311 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual PEWS measurements
Number of subjects: 108
Study 28763311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregated PEWS scores
Number of subjects: 108
Study 28532871 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural insoles
Number of subjects: 24
Study 28532871 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural insoles combined with conventional physical therapy
Number of subjects: 24
Study 25819701 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation delivered by psychological therapists
Number of subjects: 50
Study 25819701 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy based self-help introduced by CDAT workers
Number of subjects: 50
Study 23665671 — intervention group
Group type: COMPARATOR
Intervention: 3 ml normal saline with 1:200,000 epinephrine per tonsil (Group 1)
Number of subjects: 172
Study 23665671 — intervention group
Group type: COMPARATOR
Intervention: 3 ml 1% lidocaine with 1:200,000 epinephrine per tonsil (Group 2)
Number of subjects: 172
Study 23665671 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ml normal saline with 1:200,000 epinephrine per tonsil (Group 3)
Number of subjects: 172
Study 23665671 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ml lidocaine with 1:200,000 epinephrine per tonsil (Group 4)
Number of subjects: 172
Study 21110406 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy
Number of subjects: 16
Study 21110406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural psychotherapy
Number of subjects: 16
Study 21110406 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Processes Coding System
Number of subjects: 16
Study 19484917 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 1195
Study 19484917 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.4 mg/24 h rivastigmine patch
Number of subjects: 1195
Study 19484917 — intervention group
Group type: COMPARATOR
Intervention: rivastigmine capsule (3 to 6 mg twice-daily)
Number of subjects: 1195
Study 17784901 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement
Number of subjects: 215
Study 17784901 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet
Number of subjects: 215
Study 17784901 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study 15549661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg/d for 3 weeks)
Number of subjects: 27
Study 15549661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 weeks)
Number of subjects: 27
Study 15549661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 27
Study 10617956 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:1 LA:ALA formula
Number of subjects: 73
Study 10617956 — intervention group
Group type: EXPERIMENTAL
Intervention: 10:1 LA:ALA formula
Number of subjects: 73
Study 10617956 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 73
Study 10617956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formula-fed groups
Number of subjects: 73
Study 10617956 — intervention group
Group type: EXPERIMENTAL
Intervention: All formula-fed and breast-fed infants
Number of subjects: 73
Study 9075261 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual substitution of zopiclone for the initial BZD (Group A)
Number of subjects: 1002
Study 9075261 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt substitution of zopiclone for the initial BZD (Group B)
Number of subjects: 1002
Study 9075261 — intervention group
Group type: COMPARATOR
Intervention: Initial BZD (Group C)
Number of subjects: 1002
Study 1632998 — intervention group
Group type: EXPERIMENTAL
Intervention: In-chart checklist prompt for increasing screening, counseling, and referral for 11 risk behaviors
Number of subjects: 0
Study 1632998 — intervention group
Group type: EXPERIMENTAL
Intervention: In-chart checklist prompt for patients receiving gynecologic care and birth control
Number of subjects: 0
Study 6377997 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months
Number of subjects: 1019
Study 6377997 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 3 months
Number of subjects: 1019
Study 6377997 — intervention group
Group type: COMPARATOR
Intervention: Standard 12‐month control regimen
Number of subjects: 1019
Study 6377997 — intervention group
Group type: COMPARATOR
Intervention: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 12 months
Number of subjects: 1019
Study 6377997 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective chemotherapy (antituberculosis chemotherapy not started until disease confirmed active)
Number of subjects: 1019
Study 30325658 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0
Study 30325658 — intervention group
Group type: EXPERIMENTAL
Intervention: GH antagonist treatment
Number of subjects: 0
Study 28440680 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 4mg
Number of subjects: 145
Study 28440680 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 8mg
Number of subjects: 145
Study 28440680 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 145
Study 28440680 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 1mg
Number of subjects: 145
Study 28440680 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 2mg
Number of subjects: 145
Study 26232355 — intervention group
Group type: EXPERIMENTAL
Intervention: Any CAM use
Number of subjects: 401
Study 26232355 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 401
Study 26232355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary change
Number of subjects: 401
Study 26232355 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 401
Study 26232355 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived helpfulness of CAM
Number of subjects: 401
Study 26984931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon catheter
Number of subjects: 0
Study 22076877 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral catheterization
Number of subjects: 736
Study 22076877 — intervention group
Group type: COMPARATOR
Intervention: Jugular catheterization
Number of subjects: 736
Study 22076877 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis sessions through femoral catheters
Number of subjects: 736
Study 22076877 — intervention group
Group type: COMPARATOR
Intervention: Dialysis sessions through jugular catheters
Number of subjects: 736
Study 20662423 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety enhancement program
Number of subjects: 185
Study 20662423 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 185
Study 18713891 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (Group II, n = 30)
Number of subjects: 90
Study 18713891 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine (Group III, n = 30)
Number of subjects: 90
Study 18713891 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (Group I, n = 30, control)
Number of subjects: 90
Study 15654716 — intervention group
Group type: EXPERIMENTAL
Intervention: LED photomodulation using a full panel 590 nm non‐thermal full face LED array delivering 0.1 J/cm(2)
Number of subjects: 90
Study 15654716 — intervention group
Group type: EXPERIMENTAL
Intervention: LED photomodulation
Number of subjects: 90
Study 12568433 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (15-week, 45-hour) on caring for terminally ill persons
Number of subjects: 115
Study 12568433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 115
Study 10655953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (10 g daily)
Number of subjects: 54
Study 8762415 — intervention group
Group type: EXPERIMENTAL
Intervention: PD + Traditional Chinese Medicine (TCM)
Number of subjects: 0
Study 8762415 — intervention group
Group type: EXPERIMENTAL
Intervention: PD + TCM
Number of subjects: 0
Study 1987105 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% ophthalmic solution, 1 drop twice daily for 14 days
Number of subjects: 15
Study 1987105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 418431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide tablets
Number of subjects: 41
Study 418431 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate injections
Number of subjects: 41
Study 31831042 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (n=104)
Number of subjects: 222
Study 31831042 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy alone (n=118)
Number of subjects: 222
Study 28618097 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated technique
Number of subjects: 29
Study 28618097 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 29
Study 26142578 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic classifier (GC) test results
Number of subjects: 11
Study 26142578 — intervention group
Group type: COMPARATOR
Intervention: Clinical information alone
Number of subjects: 11
Study 26142578 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic classifier (GC) test results indicating high metastatic risk
Number of subjects: 11
Study 26142578 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic classifier (GC) test results indicating low metastatic risk
Number of subjects: 11
Study 23640204 — intervention group
Group type: EXPERIMENTAL
Intervention: 28‐mm bearing couple
Number of subjects: 60
Study 23640204 — intervention group
Group type: EXPERIMENTAL
Intervention: 36‐mm bearing couple
Number of subjects: 60
Study 23640204 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 42‐mm bearing couple
Number of subjects: 60
Study 21860143 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet joints infiltration (FJI) with depot methylprednisolone
Number of subjects: 18
Study 21860143 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy with McKenzie regimen
Number of subjects: 18
Study 19222614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist (DA)
Number of subjects: 4380
Study 19222614 — intervention group
Group type: COMPARATOR
Intervention: Levodopa therapy alone
Number of subjects: 4380
Study 18021950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 64
Study 18021950 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal pulse amplitude (TPA) biofeedback training
Number of subjects: 64
Study 18021950 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 64
Study 17406754 — intervention group
Group type: COMPARATOR
Intervention: IFN 3 MU thrice weekly + ribavirin 1.0‐1.2 g daily for 48 weeks (IFN TIW)
Number of subjects: 93
Study 17406754 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 3 MU daily + ribavirin 1.0‐1.2 g daily for 12 weeks followed by IFN 3 MU thrice weekly + ribavirin 1.0‐1.2 g daily for 48 weeks (IFN QD)
Number of subjects: 93
Study 17406754 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (intention to treat analysis)
Number of subjects: 93
Study 17406754 — intervention group
Group type: EXPERIMENTAL
Intervention: Among subjects with HCV genotype‐1
Number of subjects: 93
Study 17406754 — intervention group
Group type: EXPERIMENTAL
Intervention: Among patients with HCV genotype 2 or 3
Number of subjects: 93
Study 12793140 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (capoten) 25‐75 mg/day for 4 weeks
Number of subjects: 54
Study 12793140 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (lotensin) 5‐30 mg/day for 24 weeks
Number of subjects: 54
Study 9988412 — intervention group
Group type: EXPERIMENTAL
Intervention: Human endometrial stromal cells (group B)
Number of subjects: 0
Study 9988412 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A) - embryos cultured alone
Number of subjects: 0
Study 7778148 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol given 2 h after quinine (n = 7)
Number of subjects: 21
Study 7778148 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol given 2 h before quinine (n = 7)
Number of subjects: 21
Study 7778148 — intervention group
Group type: COMPARATOR
Intervention: Quinine alone (n = 7)
Number of subjects: 21
Study 7778148 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature reduction of 1 degree C
Number of subjects: 21
Study 2212378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of Fluosol-DA 20%
Number of subjects: 10
Study 2212378 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 10
Study 506975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified cereal (providing 25% US Recommended Dietary Allowance per 1 ounce serving)
Number of subjects: 96
Study 506975 — intervention group
Group type: COMPARATOR
Intervention: Non-zinc-fortified cereals
Number of subjects: 96
Study 506975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified cereal
Number of subjects: 96
Study 31927748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone (4.5 g cumulative dose during 12 weekly infusions)
Number of subjects: 15
Study 31927748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone
Number of subjects: 15
Study 31927748 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 15